Lilly opens fourth US Gateway Labs site

Iona Everson | September 26, 2025 | News story | Research and Development |  Eli Lilly, Local Investment, biotech, life sciences 

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, expanding its network of shared innovation hubs designed to support early-stage biotechnology companies.

Companies working in Gateway Labs focus on an array of therapeutic approaches and disease areas. The new facility can accommodate 15 life sciences companies and more than 250 employees of LGL-based companies, offering over 82,000 square feet of laboratory and office space.

Daniel Skovronsky, chief scientific officer and president, Lilly Research Laboratories and Lilly Immunology, said: “The future of medicine depends on combining the strengths of academia, biotech and large pharma to solve some of the most difficult diseases facing patients.”

Advertisement

In addition to having access to lab facilities, start-ups working in Gateway Labs are also able to benefit from tailored scientific engagement and strategic guidance as they work to navigate the complexities of drug discovery and development.

Lilly now has four Gateway Labs sites in the US, with one in San Diego, two in South San Francisco and one in Boston. There is also a newly opened LGL site in Beijing, as the Gateway Labs sites expand globally.

Julie Gilmore, vice president and global head of Lilly Gateway Labs and Catalyze360 Portfolio Management commented: “As we expand in innovation centres such as San Diego, we’re continuing our focus on scaling sustainably while preserving a hands-on approach that makes a meaningful difference for our partners.”

Related Content

Cellbyte raises $2.75m to fund pharma drug launch platform

Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Lilly secures conditional MHRA approval for new blood cancer treatment

Crown Bioscience opens new US model development centre

Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …

The Gateway to Local Adoption Series

Latest content